serum levels of the mcp-1 chemokine in patients with ischemic stroke and myocardial infarction患者血清mcp-1趋化因子的缺血性中风和心肌梗死.pdf

Mediators of Inflammation • 2005:3 (2005) 175–179 • PII: S0962935105502047 • DOI: 10.1155/MI.2005.175 SHORT COMMUNICATION Serum Levels of the MCP-1 Chemokine in Patients With Ischemic Stroke and Myocardial Infarction A. Arakelyan,1, 2 J. Petrkova,3 Z. Hermanova,1 A. Boyajyan,2 J. Lukl,3 and M. Petrek1 1Department of Immunology, Palacky University Olomouc, 77520 Olomouc, Czech Republic ´ 2Institute of Molecular Biology of the National Academy of Sciences of Armenia, Yerevan, Armenia 3Department of Internal Medicine I, Palacky University and Faculty Hospital Olomouc, 77520 Olomouc, Czech Republic ´ Received 4 February 2005; accepted 22 February 2005 Chemokine-driven migration of inflammatory cells has been implicated in pathogenesis of atherosclerosis-associated conditions such as ischemic stroke and myocardial infarction. In this study, a candidate chemokine, monocyte chemoattractant protein (MCP)- 1, was investigated in patients with both aforementioned manifestations of atheroslerotic inflammation. MCP-1 levels in serum were determined by ELISA in 40 healthy, control subjects (C), 40 patients with ischemic stroke (IS), and in 64 patients with myocardial infarction (MI). Statistical analysis utilised Mann-Whitney test, Fisher’s exact test, and Spearman’s rank correlation (P .05). In comparison to control subjects (C; median/interquartile range: 239/126 pg/mL), MCP-1 serum levels were increased in both inves- tigated patient cohorts (IS: 384/370, P .001; MI: 360/200, P .002). There was a substantial variability of MCP-1 serum levels, especially in the IS group. No relationship was observed between chemokine levels and atherosclerosis risk factors (